{"id":226349,"date":"2026-09-02T15:57:42","date_gmt":"2026-09-02T10:27:42","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=226349"},"modified":"2026-09-02T15:57:44","modified_gmt":"2026-09-02T10:27:44","slug":"omaxe-share-price-sat-dismisses-sebi-appeal-1-september-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/omaxe-share-price-sat-dismisses-sebi-appeal-1-september-2026\/","title":{"rendered":"Omaxe Share Price Gains as SAT Rejects SEBI Appeal"},"content":{"rendered":"
<\/div>\n

Omaxe share price up 4.98% at Rs 132, 52-wk high Rs 137.85. SAT dismisses appeal against SEBI’s 2-year market ban over financial irregularities.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Omaxe share price rose 4.98 percent to Rs 132 even after the Securities Appellate Tribunal dismissed the company’s appeal against a SEBI order that barred Omaxe, Rohtas Goel, Mohit Goel and three others from the securities market for two years. SEBI had alleged financial misrepresentation and fraudulent transactions aimed at maintaining Omaxe’s share price and promoter collateral value. The stock touched a 52-week high of Rs 137.85 during the session despite the adverse ruling.<\/p>\n<\/div>\n

The Omaxe share price<\/a> rose 4.98 percent to Rs 132, touching a 52-week high of Rs 137.85 intraday, even as the Securities Appellate Tribunal dismissed the real estate developer’s appeal against a SEBI order barring Omaxe and several of its promoters from the securities market for two years.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

SEBI had originally barred Omaxe, along with Rohtas Goel, Mohit Goel and three others, alleging financial misrepresentation and fraudulent transactions aimed at maintaining Omaxe’s share price and the value of promoter collateral. The Tribunal’s dismissal of the company’s appeal upholds this two-year market ban.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n